All Stories

  1. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals
  2. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5
  3. Association between cervical disc disease and lesions of multiple sclerosis
  4. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
  5. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  6. EAN guideline on palliative care of people with severe, progressive multiple sclerosis
  7. Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course
  8. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis
  9. Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
  10. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis
  11. Immunological Aspects of Approved MS Therapeutics
  12. B Cell-based Therapies for Multiple Sclerosis
  13. Therapies for multiple sclerosis targeting B cells
  14. A retrospective analysis of the development of seizure frequency in patients with seizures during a period of military conflict
  15. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis
  16. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
  17. Therapeutic strategies targeting B-cells in multiple sclerosis
  18. Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
  19. Revised diagnostic criteria of multiple sclerosis
  20. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
  21. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
  22. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
  23. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
  24. Stroke in the Very Elderly: Characteristics and Outcome in Patients Aged =85 Years with a First-Ever Ischemic Stroke
  25. The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors
  26. Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review
  27. In Memoriam: Hillel S. Panitch, MD (1940-2010)
  28. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease
  29. Combination therapy in multiple sclerosis
  30. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
  31. Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel
  32. Translational Research in Neurology and Neuroscience 2010
  33. Multiple sclerosis: Geoepidemiology, genetics and the environment
  34. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
  35. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke
  36. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
  37. Local corticosteroid treatment for carpal tunnel syndrome: A 6-month clinical and electrophysiological follow-up study
  38. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial
  39. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PR...
  40. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
  41. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
  42. Multiple Sclerosis
  43. The utility of the Visual Analogue Scale for the assessment of depressive mood in cognitively impaired patients
  44. The Myelin-Associated Oligodendrocytic Basic Protein Region MOBP15–36 Encompasses the Immunodominant Major Encephalitogenic Epitope(s) for SJL/J Mice and Predicted Epitope(s) for Multiple Sclerosis-Associated HLA-DRB1*1501
  45. Neurological features of West Nile Virus infection during the 2000 outbreak in a regional hospital in Israel
  46. Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report
  47. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases
  48. Glatiramer Acetate or Interferon-?? for Multiple Sclerosis?
  49. Effect of Propranolol and IFN-β on the Induction of MHC Class II Expression and Cytokine Production by IFN-γ in THP-1 Human Monocytic Cells
  50. Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ
  51. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions
  52. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial
  53. Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein
  54. Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells
  55. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.
  56. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
  57. Specific inhibition by the synthetic copolymer COP-1 of human T cell lines specific to myelin basic protein
  58. Tiapride as Treatment for Certain Patients with Idiopathic Torsion Dystonia
  59. Delayed epidural hematoma a review
  60. Purulent meningitis due to Pseudomonas aeruginosa successfully treated with colistin and piperacillin